DUBLIN--(BUSINESS WIRE)--The "Hemophilia Market Analysis By Type (Hemophilia A, Hemophilia B, Hemophilia C), By Treatment (On-demand, Prophylaxis), By Therapy (Replacement Therapy, Immune Tolerance Induction [ITI]Therapy, Gene Therapy), And Segment Forecasts to 2024" report has been added to ResearchAndMarkets.com's offering.
Global hemophilia market is expected to reach USD 15.2 billion by 2024.
Increasing need for diagnosis of the target population in order to initiate prophylaxis treatment and supportive government programs is expected to be the vital impact rendering driver.
The market players are predicted to adopt strategies such as pipeline product development and geographic expansion in underdeveloped and developing regions, such as Middle Eastern and West African countries.
As of 2015, federal bodies such as the World Federation Hemophilia have vast information and treatment regulation in about 172 countries, of which 20 were added in 2013, including Nigeria, Togo, Mali, Zambia, Mauritania, and others.
Competitive pricing strategy is a vital factor promoting market players' growth over the forecast period. For instance, Biogen launched Eloctate in 2014 in the U.S. at a lower price than the existing vastly used drug Advate.
Further Key Findings From the Study Suggest:
Hemophilia B is expected to grow at a rapid rate of over 6% during the forecast period. Higher emphasis on pipeline products with an extended half-life and increasing incidence of hemophilia B affected patients are expected to be the prominent growth factors.
On-demand treatment dominated the segment over the forecast period and is expected to contribute more than 50% by 2024. However, prophylaxis is expected to be the fastest growing segment because of the requirement for better control of bleeding episodes and growing financial assistance programs by healthcare providers and industry players.
For instance, Grifols has launched the AlphaNine SD Copay Card and ALPHANATE Copay Program for immediate enrollment in prophylaxis treatment by patients.
On the basis of therapy, gene therapy is expected to be the fastest growing segment as a result of increasing R&D and innovations in the field. Furthermore, replacement therapy is expected to witness lucrative growth due to the launch of extended half-life versions of currently available drugs.
For instance, Novo Nordisk is working on N8-GP, CSL Behring is working on CSL689 rVIIa-FP, and Bayer is working on BAY 94-9027. These are expected to be commercially available around 2017/2018. This is expected to improve treatment over the forecast period thereby boosting growth.
Major market players include Biogen, Novo Nordisk, Baxalta, Octapharma, CSL Behring, Pfizer, Inc., and Bayer Healthcare. Most of the companies are actively involved in the awareness and treatment programs launched by regional governments and hemophilia associations. Majority of their products that are awaiting FDA approval have extended therapeutic use in adults as well as children.
Key Topics Covered
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
1.3. List of Data Sources
2. Executive Summary
2.1. Hemophilia: Industry Snapshot and Key Buying Criteria, 2015 - 2024
3. Hemophilia Industry Outlook
3.1. Market Segmentation
3.2. Market Size and Growth Prospects
3.3. Hemophilia: Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Key Opportunities Prioritized
3.5. Industry Analysis: Porter's
3.6. Hemophilia Market PESTEL Analysis, 2015
4. Hemophilia Type Outlook
4.1. Hemophilia Market Share by Type, 2015 & 2024
4.2. Hemophilia A
4.3. Hemophilia B
4.4. Hemophilia C
5. Hemophilia Treatment Outlook
5.1. Hemophilia Market Share by Treatment, 2015 & 2024
6. Hemophilia Therapy Outlook
6.1. Hemophilia Market Share by Therapy, 2015 & 2024
6.2. Recombinant Therapy
6.3. Immune Tolerance Induction (ITI) Therapy
6.4. Gene Therapy
7. Hemophilia Regional Outlook
7.1. Hemophilia Market Share by Region, 2015 & 2024
7.2. North America
7.5. Latin America
7.6. Middle East and Africa (MEA)
8. Competitive Landscape
8.1. Novo Nordisk
8.3. Chugai Pharmaceutical Co.
8.4. Bayer Healthcare
8.5. Pfizer Inc.
8.6. Shire PLC
8.8. CSL Behring
For more information about this report visit https://www.researchandmarkets.com/r/3izx66